Elevated Circulating Osteoprotegerin and Renal Dysfunction Predict 15-Year Cardiovascular and All-Cause Mortality: A Prospective Study of Elderly Women
暂无分享,去创建一个
[1] Katherine E Henson,et al. Risk of Suicide After Cancer Diagnosis in England , 2018, JAMA psychiatry.
[2] M. Sánchez-Niño,et al. Osteoprotegerin and kidney disease , 2014, Journal of Nephrology.
[3] K. Zhu,et al. Elevated Osteoprotegerin Predicts Declining Renal Function in Elderly Women: A 10-Year Prospective Cohort Study , 2014, American Journal of Nephrology.
[4] K. Zhu,et al. Five-year decline in estimated glomerular filtration rate associated with a higher risk of renal disease and atherosclerotic vascular disease clinical events in elderly women. , 2013, QJM : monthly journal of the Association of Physicians.
[5] K. Zhu,et al. Estimated glomerular filtration rate as an independent predictor of atherosclerotic vascular disease in older women , 2012, BMC Nephrology.
[6] W. März,et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] J.,et al. The New England Journal of Medicine , 2012 .
[8] S. Aakhus,et al. Osteoprotegerin levels predict mortality in patients with symptomatic aortic stenosis , 2011, Journal of internal medicine.
[9] K. Zhu,et al. A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women , 2009, Clinical endocrinology.
[10] B. Kestenbaum,et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. , 2009, Journal of the American Society of Nephrology : JASN.
[11] I. Jaussent,et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[12] E. Clark,et al. Regulation of dendritic cell survival and cytokine production by osteoprotegerin , 2009, Journal of leukocyte biology.
[13] A. Levin,et al. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage 4 and 5 patients in addition to vascular calcification. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[14] P. Bakke,et al. Systemic inflammatory markers in COPD: results from the Bergen COPD Cohort Study , 2009, European Respiratory Journal.
[15] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[16] F. Corallini,et al. Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin. , 2009, European journal of histochemistry : EJH.
[17] A. J. Bass,et al. A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. , 2008, Australian health review : a publication of the Australian Hospital Association.
[18] M. Matsuhisa,et al. Serum Osteoprotegerin as a Screening Tool for Coronary Artery Calcification Score in Diabetic Pre-Dialysis Patients , 2008, Hypertension Research.
[19] I. Jaussent,et al. Fine-tuning of the prediction of mortality in hemodialysis patients by use of cytokine proteomic determination. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[20] J. Herlitz,et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. , 2008, Journal of the American College of Cardiology.
[21] P. Kostenuik,et al. Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr(−/−) Mice , 2008, Circulation.
[22] A. Khera,et al. Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). , 2007, The American journal of cardiology.
[23] F. Islam,et al. No associations between OPG gene polymorphisms or serum levels and measures of osteoporosis in elderly Australian women. , 2007, Bone.
[24] S. Thiel,et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. , 2006, Journal of the American Society of Nephrology : JASN.
[25] A. Lahiri,et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. , 2006, Journal of the American College of Cardiology.
[26] Richard L Prince,et al. Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. , 2006, Archives of internal medicine.
[27] I. Jaussent,et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.
[28] P. Olesen,et al. Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α , 2005, Diabetologia.
[29] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[30] Daniel W. Jones,et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.
[31] David L. Lacey,et al. Osteoclast differentiation and activation , 2003, Nature.
[32] KatsuhitoMori,et al. Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease , 2002 .
[33] Y. Ikari,et al. Serum Osteoprotegerin Levels Are Associated With the Presence and Severity of Coronary Artery Disease , 2002, Circulation.
[34] K. Godang,et al. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. , 2001, European journal of endocrinology.
[35] T. Shigematsu,et al. Osteoprotegerin levels before and after renal transplantation. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[36] H Britt,et al. ICPC PLUS© for Community Health? A Feasibility Study , 1997, Health information management : journal of the Health Information Management Association of Australia.
[37] G Shimamoto,et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.
[38] Brämer Gr. International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.